- Publish by :
- Source: Indica Labs and Ibex
- Dated: May 20, 2021
ALBUQUERQUE, NM and TEL AVIV, Israel – May 20, 2021 – Life Science Newswire – Indica Labs, an industry leader in quantitative digital pathology and image management solutions, and Ibex Medical Analytics, a pioneer in cancer diagnostics based on artificial intelligence (AI), announced an agreement to integrate the Galen ™ AI-based cancer diagnostics platform into the HALO AP® digital pathology workflow platform.
The HALO AP platform was developed by Indica Labs to meet the needs of digital anatomical pathology laboratories. The platform can be fully integrated into existing LIS or HIS solutions or can function as a stand-alone case and image management system for anatomical pathology. In addition, HALO AP supports a full range of tissue-based analysis and workflows, including synoptic reports, tumor tables, secondary consultations, quantitative analysis, and assisted workflows. IA. HALO AP is used by some of the largest anatomical pathology laboratories in the world, including NeoGenomics and the National Cancer Institute (NCI).
Ibex’s Galen platform uses powerful artificial intelligence algorithms that help pathologists improve the quality of cancer diagnosis and deliver productivity-enhancing information that helps reduce turnaround times. Installed in laboratories around the world and used as part of daily clinical practice, Galen routinely detects misdiagnosed and misclassified cancers on scanned slides, guiding pathologists to areas of cancer to support rapid examination . In recent clinical studies, the Galen platform has demonstrated outstanding clinical results, including the highest levels of accuracy reported in the field for prostate cancer, 1 to 2 day reductions in total treatment time and a productivity gain of 37% for pathologists, compared to the conventional microscope. visualization.
The integration between HALO AP and the Galen platform is designed to enable a seamless experience for the end user. Galen adds cancer detection, case prioritization, grading and other AI-powered productivity-enhancing information displayed directly in the HALO AP platform, so there’s no need to use a viewer distinct. If necessary, the data will be communicated automatically to the LIS or HIS system.
“As Indica Labs continues to develop its pipeline of cutting-edge AI applications, we also recognize the importance of interoperability with other leaders in this growing field,” commented Steven Hashagen, CEO of Indica. Labs. “A truly seamless integration with Ibex will allow customers to make the best AI selections without compromising usability.”
“Integrated digital pathology and AI workflows are a major driver in supporting pathologists as they face ever-increasing workloads and the complexity of diagnosing cancer,” said Joseph Mossel, CEO and co-founder of Ibex Medical Analytics. “By partnering with Indica Labs, we can jointly deliver end-to-end solutions that enable pathologists to accelerate the adoption of new technologies, strengthen the business case for digitalization, and improve the quality of care against the cancer.”
About Indica Labs
Indica Labs is the world’s leading provider of computational pathology software and services. Our flagship HALO image analysis platform enables rapid quantitative assessment of tissue using a wide range of artificial intelligence (AI) and computer vision algorithms. HALO Link and HALO AP make it easy to analyze, collaborate and manage images remotely. Through a combination of precision, scalability and ease of use, our software solutions enable pharmaceutical companies, diagnostic laboratories, research organizations and Indica’s own contracted pharmaceutical services team to advance research, clinical trials and tissue-based diagnostics. For more information visit www.indicalab.com or send an email to [email protected]
About Ibex Medical Analytics
Ibex uses artificial intelligence to develop clinical-grade solutions that help pathologists detect and classify cancer in biopsies. The Galen ™ platform is the first-ever AI-powered cancer diagnostic solution used in routine pathology clinics and deployed worldwide, enabling pathologists to improve diagnostic accuracy, integrate control comprehensive quality and enable more efficient workflows. Ibex solutions are based on deep learning algorithms trained by a team of pathologists, data scientists and software engineers. For more information, visit www.ibex-ai.com.